Monopar Therapeutics Inc. Payments to Acquire Debt Securities, Available-for-sale
Monopar Therapeutics Inc. (MNPR) reported Payments to Acquire Debt Securities, Available-for-sale of $0 for the 12-month period ending 2022-12-31, per its 10-Q filed 2023-11-09.
Discontinued › Cash Flow
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2023-11-09
| Period end | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|
| 2022-12-31 | $0.00 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |